Moderna vaccine data questioned share price plunges, chairman steps out to “fire”

BEIJING, Tuesday , the chairman of U.S. biotech company Moderna said Wednesday that the company will never release data on whether its coronavirus vaccine does nats “the actual situation.” On Monday, Moderna said in a statement on its official website that the company’s high-profile human clinical trial of the new coronavirus vaccine mRNA-1273 has “welcome” data.

The company’s shares jumped as a result of the news, rising 19.96 percent to Monday’s close, giving it a market capitalisation of more than $29.6 billion. According to Bloomberg, Goldman Sachs, the investment bank, has a 75 percent probability of success for the Moderna vaccine, up from 70 percent previously.

But just a day later, Moderna was met with “cold water” from industry experts, who questioned the clinical data on its new coronavirus vaccine, mRNA-1273, and concluded that “a lot of narrative and very limited data” from Moderna’s statement was not enough to prove that the vaccine itself was good or bad.

In addition, investors have found that, at a time when Moderna’s share price has soared, the company’s CEO, Stephen K. Stephane Bancel continues to reduce its holdings.

As a result, Moderna’s shares fell 10.41 percent on Tuesday and fell nearly 6 percent in after-hours trading. By Tuesday’s close, Moderna’s market value had shrunk to $26.6 billion, down more than $3 billion.

Moderna said in a statement Monday that all eight of the 45 subjects tested produced neutralizing antibodies against the neo-coronavirus, which are equal to or higher than the serum levels of the recovering person, and that neutralizing antibodies are thought to be effective in preventing virus infection and eliminating the virus. In addition, 45 subjects had adverse inoculation reactions within acceptable limits.

But as the good news continues to spread, many doubts are beginning to surface. On Tuesday, the U.S. health news site Stat, in an interview with several vaccine experts, noted that it was impossible to tell whether the vaccine itself was good or bad, based on Amodern’s statement.

In the face of questions, Moderna chairman Noubar Afeyan, who has made an urgent appearance to “fight the fire,” told CNBC, a US financial news agency, on Wednesday that the company would never publish data that differed from “actual” data for its potential coronavirus vaccine.

“We take what we do very seriously,” he said. We won’t, and never did, come up with data to make anything look any different from what it really is. “

Some experts may “guess what we may or may not have in order to be professional, ” Afyan said. “It’s not very useful for a world that’s looking for news that they can read. I just want to urge the public to pay attention to what we have said. “

Moderna shares closed up 2.5 per cent at $73.47 on Wednesday.